Compare NNNN & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNNN | MSD |
|---|---|---|
| Founded | 2021 | 1993 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.1M | 136.4M |
| IPO Year | 2023 | N/A |
| Metric | NNNN | MSD |
|---|---|---|
| Price | $3.81 | $6.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.9K | ★ 84.7K |
| Earning Date | 11-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.09 | $6.61 |
| 52 Week High | $44.73 | $7.94 |
| Indicator | NNNN | MSD |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 45.58 |
| Support Level | $3.21 | $6.61 |
| Resistance Level | $6.95 | $7.44 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 42.92 | 40.32 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.